CSMD1 and gastric cancer: Significant features, including upregulation of the immune pathway, enrichment of the anti-tumor immune cells in a tumor microenvironment, the reduction in tumor-promoting immune cells, a high TMB, a high MSI status, and the upregulation of PD-L1, indicated that gastric cancer patients with CSMD1-mut may benefit from anti-PD-L1.